Lirafugratinib, also known as RLY-4008, is a tyrosine kinase inhibitor with potential antineoplastic activity. Lirafugratinib binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.
MedKoo Cat#: 130035
Name: Lirafugratinib
CAS#: 2549174-42-5 (free base)
Chemical Formula: C28H24FN7O2
Exact Mass: 509.1976
Molecular Weight: 509.54
Elemental Analysis: C, 66.00; H, 4.75; F, 3.73; N, 19.24; O, 6.28
The following data is based on the product molecular weight 509.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
